Why Indian pharma isn't scared of a 100% tariff (yet)
Topics discussed
Trump's 100% generic drug tariff announcement and market reaction
Why the market is panicking despite a two-year delay
Tariff timeline, escalation to 200%, and policy context
Podcast introduction and listener survey request
Impact on consumers: price hikes and supply shortages
Economic data: cost of generics vs. patented drugs
Previous tariff refunds and household financial burden
Indian pharma companies positioned to benefit from tariffs
Why shifting manufacturing to the US is impractical
China's dominance in Active Pharmaceutical Ingredients (APIs)
History of previous tariff announcements and market dips
Conclusion: Who ultimately bears the burden?
Outro and subscription promotion
Listen ad-free on Castria